Necrotising myositis is a rare muscle disease where the immune system mistakenly attacks healthy muscle tissue, causing muscle cell death and progressive weakness. Treatment focuses on slowing disease progression, managing symptoms, and helping patients regain strength through a combination of immune-suppressing medications and lifestyle adjustments.

Understanding Treatment Goals for Necrotising Myositis

When someone is diagnosed with necrotising myositis, also called immune-mediated necrotising myopathy or IMNM, the main aim of treatment is to stop the body’s immune system from continuing to attack the muscles. This disease causes necrosis, which means muscle cells die, leading to symmetrical weakness that affects both sides of the body, particularly in muscles close to the center like the shoulders, hips, and thighs.^[1]

The approach to treatment depends heavily on several factors. The severity of symptoms at the time of diagnosis matters greatly. Some people experience rapid onset with severe weakness developing over days or weeks, while others have a slower progression over months. The presence or absence of specific autoantibodies in the blood—immune system proteins that attack the body’s own tissues—also influences which medications doctors choose. Additionally, the patient’s age, overall health, and whether the disease is linked to statin medications or other triggers all shape the treatment plan.^[2]

There is currently no cure for necrotising myositis. However, medical societies and specialists have developed treatment guidelines based on clinical experience and research. These standard approaches are used worldwide to help manage the disease. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative medications and approaches that may offer better outcomes for patients in the future.^[9]

Standard Treatment Approaches

The foundation of treatment for necrotising myositis involves medications that suppress the immune system, preventing it from continuing to damage muscle tissue. Because the disease is caused by the immune system mistakenly attacking the body’s own muscles, controlling this abnormal immune response is essential.^[12]

Corticosteroid Therapy

Corticosteroids, particularly prednisone, are typically the first medications prescribed. These drugs work by reducing inflammation and suppressing the overactive immune response that causes muscle damage. Prednisone is often started at high doses and then gradually reduced as the patient’s condition improves. The medication helps decrease swelling in the muscles and allows them to begin healing.^[12]

However, long-term use of high-dose corticosteroids can cause unwanted side effects. Patients may develop a condition called steroid myopathy, which is muscle weakness caused by the steroids themselves. Other side effects include decreased bone density, which increases the risk of fractures, weight gain, fluid retention causing swelling, and increased susceptibility to infections. Because of these potential complications, doctors carefully monitor patients and aim to use the lowest effective dose.^[12]

Additional Immunosuppressive Medications

Many patients require additional medications beyond corticosteroids to control the disease. These drugs work through different mechanisms to suppress the immune system. Commonly used options include azathioprine, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine. Each has its own profile of effectiveness and potential side effects.^[12]

The choice of which medication to use often depends on the specific type of necrotising myositis. Patients are classified into subtypes based on the autoantibodies found in their blood. Those with anti-HMGCR antibodies may respond particularly well to certain treatments, while those with anti-SRP antibodies might need different approaches.^[1]

Intravenous Immunoglobulin (IVIG)

Intravenous immunoglobulin, or IVIG, is a treatment made from antibodies collected from thousands of blood donors. It is given through an infusion directly into the bloodstream. IVIG works by modulating the immune system in ways that scientists don’t fully understand, but it can be very effective for some patients with necrotising myositis.^[12]

For patients with anti-HMGCR antibodies, IVIG may be particularly beneficial. Some research suggests that IVIG can be effective even when used alone as the primary therapy, without needing as many other immunosuppressive drugs. This is especially important because it may allow patients to avoid some of the side effects associated with long-term corticosteroid use.^[9]

Rituximab

Rituximab is a monoclonal antibody—a laboratory-made protein that targets specific cells in the immune system. Specifically, it targets B cells, which are immune cells that produce antibodies. For patients with anti-SRP antibodies, rituximab may be particularly helpful. Many specialists favor starting rituximab early in the treatment course for these patients, as this subtype tends to be more severe and less responsive to other therapies.^[9]

Combination Therapy and Treatment Duration

Most patients with necrotising myositis require combination therapy, meaning they take multiple medications at once. This approach targets the disease through different mechanisms, improving the chances of controlling symptoms and preventing further muscle damage. The specific combination is individualized based on each patient’s disease severity, autoantibody status, and response to treatment.^[9]

Treatment for necrotising myositis is typically long-term. Patients often need to stay on immunosuppressive medications for months or years. When doctors attempt to reduce or stop medications, there is a high risk of disease relapse, meaning symptoms can return. For this reason, ongoing monitoring through regular blood tests and clinical examinations is essential. Doctors measure levels of creatine kinase (CK), an enzyme released when muscle cells are damaged, to assess disease activity and treatment response.^[9]

Managing Triggers and Underlying Causes

For some patients, necrotising myositis is associated with exposure to statin medications, which are commonly prescribed to lower cholesterol. In these cases, stopping the statin is an important first step. The anti-HMGCR antibody is particularly associated with statin exposure, though not all patients with this antibody have taken statins. Dietary sources like red yeast rice and oyster mushrooms, which contain natural statin-like compounds, can also trigger the disease.^[1]

In rare cases, necrotising myositis can be associated with cancer. When this connection is suspected, treating the underlying cancer becomes an important part of managing the muscle disease. Doctors may order scans and other tests to look for hidden tumors.^[8]

Treatment Being Tested in Clinical Trials

While standard treatments can effectively manage necrotising myositis for many patients, researchers continue to search for better therapies. Clinical trials are research studies where new treatments are tested to see if they are safe and effective. These trials are conducted in phases, each with a specific purpose.^[9]

Understanding Clinical Trial Phases

Phase I trials focus primarily on safety. Researchers give the new treatment to a small group of people to determine if it causes harmful side effects and to find the right dose. Phase II trials expand to more participants and focus on whether the treatment actually works—does it improve symptoms or slow disease progression? Phase III trials involve large numbers of patients and compare the new treatment directly to standard treatments to see which works better.^[9]

Novel Immunotherapies

Researchers are exploring various new approaches to treat necrotising myositis. Some trials are investigating different monoclonal antibodies that target specific parts of the immune system. These treatments aim to be more precise than current medications, suppressing only the harmful immune responses while leaving protective immunity intact.

Other studies are looking at ways to modify existing treatments. For example, researchers are testing whether different dosing schedules or combinations of existing medications might improve outcomes. Some trials focus specifically on patients with particular autoantibody subtypes, recognizing that anti-SRP and anti-HMGCR myositis may respond differently to various treatments.^[2]

Targeting Specific Molecular Pathways

Scientists have discovered that necrotising myositis may involve the complement system, a part of the immune system that helps antibodies and cells clear pathogens and damaged cells. Some researchers believe that blocking specific components of this system might help prevent muscle damage. Experimental treatments that target complement pathways are being explored, though these are still in early stages of research.

Patient Eligibility and Trial Locations

Clinical trials for necrotising myositis are conducted at specialized medical centers, often in multiple countries. Trials may be available in the United States, Europe, and other regions. To participate, patients typically need to meet specific criteria, such as having confirmed necrotising myositis with certain autoantibodies, a specific level of disease activity, or previous treatment history.

Eligibility requirements vary by trial. Some studies accept only newly diagnosed patients who haven’t yet received treatment, while others focus on patients whose disease hasn’t responded well to standard therapies. Age, overall health status, and other medical conditions can also affect whether someone qualifies for a particular trial. Patients interested in clinical trials should discuss options with their treating physicians, who can help identify appropriate studies and facilitate enrollment.^[9]

Most common treatment methods

• Corticosteroid therapy
  • Prednisone or methylprednisolone to reduce inflammation and suppress immune response
  • Typically started at high doses and gradually reduced
  • Used as first-line treatment in most patients
  • Long-term use monitored carefully due to potential side effects including steroid myopathy, bone loss, and weight gain
• Immunosuppressive medications
  • Azathioprine to suppress overactive immune system
  • Methotrexate as alternative immunosuppressive agent
  • Mycophenolate mofetil for long-term disease control
  • Tacrolimus or cyclosporine in selected cases
  • Often used in combination with corticosteroids
• Intravenous immunoglobulin (IVIG)
  • Antibody preparation given through IV infusion
  • Particularly effective for patients with anti-HMGCR antibodies
  • May be used alone or in combination with other treatments
  • Can help reduce need for high-dose corticosteroids
• Rituximab therapy
  • Monoclonal antibody targeting B cells of immune system
  • Often favored early in treatment for patients with anti-SRP antibodies
  • Given by intravenous infusion at scheduled intervals
  • May be more effective for severe or treatment-resistant disease
• Supportive care
  • Physical therapy to improve muscle strength and prevent contractures
  • Exercise programs tailored to individual capabilities
  • Occupational therapy to help with daily activities
  • Nutritional counseling to support overall health
  • Regular monitoring with blood tests and clinical assessments
• Trigger removal
  • Discontinuation of statin medications when associated with disease
  • Avoidance of dietary sources of statin-like compounds
  • Cancer screening and treatment when malignancy is suspected

Living with Treatment and Managing Expectations

Starting treatment for necrotising myositis can feel overwhelming. Patients often need to take multiple medications, attend frequent medical appointments, and undergo regular blood tests. The first year after diagnosis is typically the most challenging, as doctors work to find the right combination of medications and patients adjust to their new reality.^[18]

It’s important to understand that improvement often takes time. Muscle strength doesn’t return overnight, and rebuilding damaged muscles requires patience and consistent effort. Some patients see significant improvement within weeks or months of starting treatment, while others experience a slower, more gradual recovery. Response to treatment varies based on the severity of initial symptoms, how quickly treatment was started, and individual factors.^[14]

Physical therapy and regular exercise play crucial roles alongside medication. As muscles begin to heal, gentle movement and progressive strengthening exercises help rebuild function. Physical therapists can design programs appropriate for each patient’s current level of ability. Starting slowly and gradually increasing activity as tolerated is key. Exercise is not just supportive—it’s considered medicine for myositis, helping maintain and improve muscle strength.^[16]

Monitoring Treatment Response

Throughout treatment, doctors use several methods to assess whether therapies are working. Blood tests measuring creatine kinase levels provide an objective marker of muscle damage. When treatment is effective, CK levels typically fall. However, some patients maintain stable muscle strength even with persistently elevated CK levels, highlighting the importance of considering both laboratory values and clinical symptoms.^[14]

Functional assessments—evaluating what patients can actually do in daily life—are equally important. Can they climb stairs more easily? Can they lift their arms overhead without difficulty? Are they less tired at the end of the day? These practical measures of improvement matter tremendously to patients’ quality of life and help guide treatment decisions.

Some patients may undergo repeat muscle biopsies to assess disease activity directly in muscle tissue. Imaging studies like MRI can also show inflammation and damage in muscles. These tools help doctors distinguish between active disease that needs more aggressive treatment and stable disease where medication doses might be maintained or carefully reduced.^[2]

Age and Prognosis

Age at disease onset appears to influence how necrotising myositis behaves and responds to treatment. Younger patients, whether children or young adults, tend to have more severe disease presentations. This can be particularly challenging, as aggressive immunosuppression in young people raises concerns about long-term effects of medications. However, with intensive treatment, even young patients with severe disease can improve significantly.^[2]

Children with necrotising myositis may initially appear to have a muscular dystrophy—a group of genetic muscle diseases—because of the severity of weakness and muscle wasting. This can delay correct diagnosis and treatment. Once properly identified and treated with immunosuppressive therapy, however, these dystrophy-like features may be reversible, which is very different from true genetic muscular dystrophies.^[2]

The Importance of Specialized Care

Necrotising myositis is a rare disease, and many general practitioners and even rheumatologists may not have extensive experience treating it. For this reason, many patients benefit from evaluation at specialized myositis centers. These centers have physicians, nurses, physical therapists, and other healthcare professionals with specific expertise in inflammatory muscle diseases.^[1]

Specialized centers are often located at major academic medical centers and teaching hospitals. They typically have access to the latest diagnostic tools, participate in clinical trials offering experimental treatments, and have experience managing complex cases. Even if ongoing care continues with a local physician, an initial evaluation or periodic consultations at a specialized center can be valuable for optimizing treatment plans.^[14]